Evidence map›Paper›PMID 42410337›Full record

ArticleBMC bioinformatics2026

A multi-view feature fusion framework with interpretable graph convolution for predicting microbe-drug associations.

Lisha Zhou

Abstract read
In one paragraph

Article in BMC bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Lisha ZhouSchool of Computer Science and Technology, Guangdong University of Technology, Guangzhou, 510006, China. 3223004734@mail2.gdut.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Predicting associations between human microbes and drugs (MDA) is a critical step in drug development and precision medicine. Although various computational approaches have been proposed, many existing models still struggle to reveal the key features and interaction mechanisms that drive their predictions, and their decision processes remain difficult to interpret and validate biologically. To address these limitations, we propose IDEAL (Interpretability-Driven Evolvable Attentive Learning for Microbe-Drug Association), a multi-view framework that integrates drug network topological attributes, BERT-encoded drug semantics, drug fingerprints, microbe genome sequence attributes, BERT-encoded microbe semantics, and microbe metabolic pathway attributes. We further introduce GNNExplainer into the graph convolutional network (GCN) pipeline to identify influential drug-microbe relations and feed the resulting structural signal back into graph refinement. In addition, we employ Elastic Weight Consolidation (EWC) to support parameter-efficient adaptation when biological data grow over time while mitigating catastrophic forgetting. Extensive experiments on three public datasets demonstrate that the proposed method achieves strong predictive performance, offers interpretable structural explanations, and provides a practical transfer-learning route for evolving MDA benchmarks. The source code for our model is publicly available at https://github.com/Luoxidu02/IDEAL .

Indexed as

BacteriaComputational BiologyGraph Neural NetworksHumansPharmaceutical PreparationsPharmaceutical PreparationsComputational biologyContinual learningInterpretable graph convolutional networkMicrobe-drug association predictionMulti-view feature fusionPre-trained language model

Identifiers

PMID42410337
PMCPMC13621604

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.